The story’s different when it comes to specialist biodesign tools – going back to our DNA synthesis scenario at the top. But the regulatory approaches that may work for big frontier labs (e.g. compute thresholds) don’t translate so well for these. The scale/capability

→ View original post on X — @nathanbenaich,